Plant Name: Anthyllis onobrychoides
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| OPRD1; NPSR1; CXCR1; NMUR2; | |
| ADRA2C; ADRA2A; ADRA2B; DRD4; | |
| ALPI; RECQL; TDP1; PLA2G1B; CTDSP1; P4HB; PIK3R1; GLO1; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALOX12; NOX4; PYGL; POLB; | |
| ACHE; GAA; | |
| PKN1; AKT1; MET; CSNK2A1; DAPK1; NEK2; FLT3; NEK6; CAMK2B; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; AXL; KDR; | |
| CA12; CA3; CA14; CA7; CA5A; CA1; CA9; CA4; CA6; CA2; | |
| AR; | |
| ESRRA; | |
| KDM4E; | |
| MAOA; ALOX5; TYR; XDH; | |
| MMP13; MMP3; MMP2; MMP9; | |
| BACE1; | |
| AHR; STAT6; HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.708E-13 | 3.364E-10 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.687E-13 | 4.587E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, MPO, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.556E-12 | 1.059E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.380E-12 | 3.652E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.046E-11 | 4.950E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.863E-10 | 1.132E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.021E-10 | 1.132E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.061E-09 | 2.785E-07 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.351E-09 | 3.198E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.351E-09 | 3.198E-07 | CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.647E-08 | 2.964E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.151E-08 | 3.718E-06 | ALPI, AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, ESRRA, GLO1, MMP13, MMP2, MMP3, MMP9, TP53 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 2.776E-08 | 4.614E-06 | ADRA2A, ADRA2B, ADRA2C, DRD4 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.766E-08 | 5.900E-06 | ADRA2A, ADRA2B, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 6.241E-08 | 9.137E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 6.497E-08 | 9.308E-06 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 9.137E-08 | 1.236E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 2.708E-07 | 3.187E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.643E-07 | 4.131E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.643E-07 | 4.131E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 4.387E-07 | 4.753E-05 | ADRA2A, ADRA2B, ADRA2C, AKT1, SRC |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 4.749E-07 | 5.069E-05 | AKT1, HIF1A, LMNA, OPRD1, P4HB, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 9.077E-07 | 9.067E-05 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.809E-06 | 1.698E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 4.049E-06 | 3.526E-04 | ADRA2B, ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 5.033E-06 | 4.315E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 8.515E-06 | 6.997E-04 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 8.912E-06 | 7.278E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 8.924E-06 | 7.278E-04 | AURKB, CA2, CA7, HIF1A, MAPK1, NEK2, NPSR1, PLA2G1B |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.030E-05 | 8.216E-04 | ADRA2A, AURKB, CA2, CA7, HIF1A, KDR, MAPK1, NEK2, NPSR1, PLA2G1B, SRC |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.047E-05 | 8.317E-04 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.122E-05 | 8.792E-04 | FLT3, HIF1A, KDR, MAPK1, PKN1, POLB, TYR |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.152E-05 | 8.990E-04 | AKT1, CYP1A2, MAPK1, MMP9 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.312E-05 | 1.002E-03 | AHR, CSNK2A1, HIF1A, KDR |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 1.648E-05 | 1.233E-03 | AKT1, MET, NEK2, PIK3R1, STAT6, TP53 |
| BP | GO:0051179; localization | GO:0046903; secretion | 1.775E-05 | 1.324E-03 | ALOX5, AXL, CA2, CA9, CXCR1, DRD4, GAA, HIF1A, MAPK1, MMP9, MPO, NFKB1, NMUR2, PLA2G1B, PYGL, XDH |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.925E-05 | 1.426E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.052E-05 | 1.494E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.052E-05 | 1.494E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.060E-05 | 1.495E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.528E-05 | 1.793E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.153E-05 | 2.200E-03 | AKT1, AR, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, SRC |
| BP | GO:0009987; cellular process | GO:0032459; regulation of protein oligomerization | 3.243E-05 | 2.234E-03 | MMP3, OPRD1, SRC, TP53 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 4.309E-05 | 2.887E-03 | ACHE, AR, HSD17B1, IGF1R, PIK3R1 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 4.559E-05 | 3.008E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.902E-05 | 3.196E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 4.931E-05 | 3.205E-03 | ADRA2B, ADRA2C, AKT1, ALOX12, AR, AXL, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, KDR, LMNA, NFKB1, PIM1, SRC, STAT6 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 5.195E-05 | 3.357E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 5.933E-05 | 3.734E-03 | AURKB, MAPK1, NEK2 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 5.933E-05 | 3.734E-03 | CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 5.933E-05 | 3.734E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 6.138E-05 | 3.797E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.138E-05 | 3.797E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.138E-05 | 3.797E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 6.138E-05 | 3.797E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 6.138E-05 | 3.797E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 6.176E-05 | 3.810E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 6.852E-05 | 4.168E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 8.702E-05 | 5.205E-03 | ADRA2A, ADRA2C, AHR, AXL, HIF1A, NFKB1, P4HB, PIK3R1, TP53, TYR |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 8.791E-05 | 5.230E-03 | ADRA2A, AKT1, HIF1A, NOX4, PIK3R1, PYGL |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 9.848E-05 | 5.796E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.005E-04 | 5.867E-03 | ADRA2B, ADRA2C, AKT1, ALOX12, AR, AXL, CA2, CAMK2B, CDK1, CTDSP1, CYP1B1, ESRRA, GSK3B, HIF1A, KDR, PIK3R1, PIM1, PTK2, SRC, STAT6, XDH |
| BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 1.069E-04 | 6.206E-03 | AKT1, GAA, GSK3B, PYGL |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 1.078E-04 | 6.229E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.078E-04 | 6.229E-03 | AKT1, AR, DAPK1, LMNA, SRC |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.145E-04 | 6.565E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0000003; reproduction | GO:0022414; reproductive process | 1.192E-04 | 6.776E-03 | ADRA2B, ADRA2C, AKR1B1, AKT1, AR, AXL, CDK1, CYP19A1, CYP1A1, HIF1A, HSD17B2, MAPK1, MMP2, MMP9, NEK2, PTK2, SRC |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.224E-04 | 6.904E-03 | NMUR2, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.224E-04 | 6.904E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.349E-04 | 7.590E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0038023; signaling receptor activity | 1.385E-04 | 7.775E-03 | ADRA2A, ADRA2B, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, ESRRA, FLT3, IGF1R, KDR, MET, NMUR2, NPSR1, OPRD1 |
| BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 1.515E-04 | 8.351E-03 | DRD4, NMUR2, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.515E-04 | 8.351E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.596E-04 | 8.755E-03 | ABCG2, CA12, CA2, CA7, DRD4, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53 |
| BP | Unclassified; | GO:0019229; regulation of vasoconstriction | 1.614E-04 | 8.809E-03 | ADRA2A, ADRA2B, ADRA2C, AKT1 |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 1.742E-04 | 9.411E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, MPO, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0097164; ammonium ion metabolic process | 1.842E-04 | 9.925E-03 | ACHE, AKR1B1, CSNK2A1, DRD4, MAOA, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.694E-21 | 7.288E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.971E-15 | 9.021E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.368E-15 | 1.067E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.729E-14 | 5.720E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.041E-20 | 5.565E-18 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.081E-12 | 4.649E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.911E-10 | 8.742E-09 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; AKT1; MAPK1; MET; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.612E-11 | 2.203E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.544E-09 | 5.651E-08 | CYP2C9; CYP2C8; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.146E-09 | 6.544E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.365E-09 | 1.403E-07 | GSK3B; AR; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.012E-08 | 2.058E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.278E-09 | 1.436E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 6.646E-08 | 9.356E-07 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; CYP2C9; CYP2C8; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; ALPI; XDH |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.759E-08 | 3.218E-07 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.166E-08 | 3.604E-07 | CYP2C9; CYP2C8; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.425E-08 | 3.699E-07 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.101E-07 | 1.259E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.992E-07 | 2.608E-06 | GSK3B; KDR; AKT1; MAPK1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 9.836E-08 | 1.200E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.612E-07 | 2.529E-06 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.625E-07 | 2.529E-06 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.850E-07 | 1.992E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.290E-08 | 9.529E-07 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.792E-07 | 2.554E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.526E-07 | 2.933E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.095E-07 | 3.258E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 6.952E-07 | 5.301E-06 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 7.557E-07 | 5.532E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.897E-07 | 6.030E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 9.968E-07 | 6.290E-06 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.707E-06 | 1.041E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.968E-07 | 6.290E-06 | OPRD1; ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.205E-07 | 5.775E-06 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.537E-06 | 2.980E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.172E-06 | 3.750E-05 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.930E-06 | 2.734E-05 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 8.976E-06 | 4.366E-05 | OPRD1; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2B; ADRA2A |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 9.066E-06 | 4.366E-05 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.706E-06 | 2.691E-05 | ALK; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.247E-06 | 1.917E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.072E-05 | 1.171E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.375E-05 | 1.261E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.677E-05 | 1.089E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 7.809E-06 | 3.970E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.036E-05 | 1.171E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.574E-05 | 1.308E-04 | LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.056E-05 | 1.427E-04 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.064E-05 | 4.748E-05 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.745E-05 | 7.427E-05 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.945E-05 | 1.707E-04 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.745E-05 | 7.427E-05 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.064E-05 | 4.748E-05 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.865E-06 | 4.629E-05 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.865E-05 | 7.757E-05 | CSNK2A1; SRC; MAPK1; MET; IGF1R |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 7.238E-05 | 2.408E-04 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.306E-04 | 4.121E-04 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.932E-05 | 2.010E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.199E-04 | 3.849E-04 | GSK3B; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.869E-05 | 1.388E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 9.601E-05 | 3.138E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.741E-04 | 5.309E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 2.113E-04 | 6.237E-04 | CAMK2B; AR; CDK1; MAPK1; IGF1R |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.637E-04 | 7.539E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 3.722E-04 | 1.048E-03 | GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 9.743E-04 | 2.547E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 4.105E-04 | 1.121E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.056E-03 | 2.648E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.402E-03 | 3.333E-03 | OPRD1; NMUR2; ADRA2C; ADRA2B; ADRA2A; DRD4 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.139E-03 | 2.808E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 9.225E-04 | 2.447E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 6.986E-04 | 1.880E-03 | CAMK2B; SRC; MMP2; MAPK1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 9.947E-04 | 2.564E-03 | CAMK2B; GSK3B; MAPK1; TYR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.863E-03 | 4.315E-03 | CAMK2B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.032E-03 | 2.624E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.235E-03 | 2.974E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.071E-03 | 4.737E-03 | SRC; AKT1; MAPK1; PIK3R1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.151E-03 | 2.808E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.756E-03 | 6.150E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.833E-03 | 4.301E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.832E-03 | 6.169E-03 | AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 2.396E-03 | 5.414E-03 | GSK3B; MAPK1; MET; PTK2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.582E-03 | 7.534E-03 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 5.736E-03 | 1.105E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.765E-03 | 7.796E-03 | CXCR1; AKT1; MAPK1; PIK3R1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 3.894E-04 | 1.080E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 4.456E-03 | 8.962E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 4.150E-03 | 8.439E-03 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.414E-04 | 4.385E-04 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 5.229E-03 | 1.018E-02 | PIM1; AKT1; STAT6; PIK3R1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 5.229E-03 | 1.018E-02 | CAMK2B; SRC; MAPK1; PIK3R1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 6.481E-03 | 1.223E-02 | BACE1; GSK3B; MAPK1; HSD17B10 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.299E-04 | 6.677E-04 | CXCR1; SRC; MET; NFKB1 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.478E-02 | 2.527E-02 | SRC; MAPK1; PIK3R1; PTK2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 9.040E-03 | 1.622E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.956E-02 | 4.434E-02 | CXCR1; FLT3; KDR; MET |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.616E-02 | 3.990E-02 | AKT1; MAPK1; TP53; NFKB1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 2.348E-02 | 3.736E-02 | CSNK2A1; SRC; AKT1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.742E-02 | 2.855E-02 | GSK3B; CDK1; TP53 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.742E-02 | 2.855E-02 | AKT1; PIK3R1; IGF1R |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.006E-02 | 1.770E-02 | CAMK2B; AKT1; PYGL |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 9.791E-03 | 1.740E-02 | PIK3R1; NFKB1; PTK2 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 8.032E-03 | 1.455E-02 | AKT1; MAPK1; PIK3R1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 6.900E-03 | 1.288E-02 | SRC; CDK1; MAPK1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 3.356E-03 | 7.141E-03 | AKT1; MAPK1; PIK3R1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 6.475E-03 | 1.223E-02 | MAPK1; PKN1; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.833E-05 | 1.127E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 2.826E-03 | 6.169E-03 | AKT1; PIK3R1; IGF1R |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.791E-03 | 7.796E-03 | CA2; CYP3A4; ABCG2 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.953E-03 | 6.357E-03 | SRC; MAPK1; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 3.329E-02 | 4.952E-02 | STAT6; NFKB1 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 2.873E-02 | 4.345E-02 | MAPK1; IGF1R |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.528E-02 | 3.920E-02 | AKT1; PIK3R1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.612E-02 | 3.990E-02 | MAPK1; NFKB1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.444E-02 | 3.856E-02 | GSK3B; TP53 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 2.528E-02 | 3.920E-02 | GAA; PYGL |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.969E-02 | 3.160E-02 | MAOA; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.894E-02 | 3.067E-02 | MAPK1; PIK3R1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.676E-02 | 2.814E-02 | AKT1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.748E-02 | 2.855E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.606E-02 | 2.722E-02 | ABCC1; ABCG2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.276E-02 | 2.203E-02 | MAPK1; PIK3R1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 7.686E-03 | 1.407E-02 | GAA; AKR1B1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 7.194E-03 | 1.330E-02 | MAPK1; TP53 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.036E-02 | 1.806E-02 | MAOA; TYR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.560E-03 | 9.071E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.898E-04 | 5.693E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ESRRA; ALOX5; OPRD1; MMP3; CAMK2B; TYR |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9; IGF1R; CYP19A1; CDK1; KDR; KDR; KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADRA2C; CA1; CA1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; ADRA2C |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | HIV infections | NA | AHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; CSNK2A1; FLT3; FLT3; CA9; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; TP53; CA1; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; OPRD1; CAMK2B; ACHE; CYP3A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; ACHE; ACHE; ACHE; GSK3B; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; ADRA2B |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; KDR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1 |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; KDR |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; MMP13; OPRD1; ACHE; IGF1R; CDK1; ADRA2C; ADRA2A |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; OPRD1; ADRA2C; ADRA2B |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |